The global toxicology drug screening market is anticipated to reach US$ 70.80 billion by 2033, up from US$ 25.99 billion in 2023 advancing at a rapid CAGR of 10.5% during the forecast period. The demand for toxicology drug screening is on the surge as toxicology screening process can be done very quickly and provides approximate results showing the presence of specific drug in the system.
Toxicological screening is done for four primary purposes that includes medical testing, employment drug testing, forensic analysis, and athletics testing and the adoption of the same rises as it enables control in consumption of illegal drugs.
A doctor or physician performs a toxicology screen in case of accidents or sexual assaults on a person if suspected with the drug intoxication or overdose symptoms including unconsciousness, panic attacks, chest pain, deliriousness, and seizures. Furthermore, the toxicology drug screening market growth is fostered by its use before undergoing an organ transplant, drug abuse, during pregnancy.
| Attributes | Details |
|---|---|
| Historical Value (2022) | US$ 23.88 billion |
| Current Year Value (2023) | US$ 25.99 billion |
| Expected Forecast Value (2033) | US$ 70.80 billion |
| Historical CAGR (2018 to 2022) | 8.8% |
| Projected CAGR (2023 to 2033) | 10.5% |
Toxicology drug screening find vast applications in food and beverage industries, chemical industries, cosmetics and households and pharmaceutical companies which augments the adoption of toxicology drug screening.
These screening tests are majorly intended for detection of illegal drugs in victim’s blood or urine sample. Biochemical assays, cellular assays, reagents and kits, in silico services are the major type of toxicological drug screening products available in the industry.
Many of these screening tests are performed to determine systemic toxicity, carcinogenicity, dermal toxicity, genotoxicity, neurotoxicity, and organ-specific toxicity and thus contribute majorly to the revenue generation in toxicology drug screening market.
The toxicology drug screening market outlook is swayed by these toxicology drug screening methods as they are performed using various high-end technologies such as high-throughput screening, genomics, transcriptomics, and molecular screening.
The increasing usage of toxicological screening generates large revenues in the toxicology drug screening market owing to their growing demand in hospitals and trauma centers, rehabilitation centers and forensic laboratories.
Increasing adoption of in-vitro methods to detect toxic drugs in human system tends to propel the growth of toxicology drug screening market across the globe and registers a significant revenue growth in the toxicology drug screening market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Growing technological advancements leading to development of novel screening products are majorly contributing to the rising adoption of toxicology drug screening worldwide. Moreover, increasing availability of high-end drug screening instruments, reagent and kits coupled with wide application areas for toxicology drug screening are also expected to drive the growth of toxicology drug screening market.
Introduction of rapid and automated toxicity detection technologies, increasing government expenditure on toxicity testing and favorable reimbursement policies in toxicity screening is further fostering the toxicology drug screening market. Also, rise in demand for toxicology drug screening in the food and beverage industry, and chemical industry is also expected to drive the overall market growth.
However, inadequate efficacy of conventional techniques and longer time taken by laboratories for sample testing are some of the factors restraining the toxicology drug screening market during the forecast period.
| Regions | 2022 Value Share in Global Market |
|---|---|
| North America | 43.1% |
| Europe | 32.3% |
On account of the expanding research and development activities in this area to detect toxicity levels in the human body at early stages, North America held a market share of 43.1% in 2022. As these trials are being outsourced to other locations, such as Asia, research and development in this region has hit a plateau.
In addition, pharmaceutical companies' R&D expenses have increased in recent years, owing to the increasing burden of diseases, therapy sectors, and complex compounds, expanding the toxicology drug screening market size in the region.
Europe had a 32.3% market share in toxicological drug screening in 2022 primarily due to growing R&D activities to detect toxicity levels in the human body at early stages.
Regulatory approvals, new products, and product launches are projected to drive the growth of the Europe drug screening market during the forecast period.
Furthermore, rising government financing is expected to move the European toxicology drug screening market forward.
Principal Consultant
| Countries | 2022 Value Share in Global Market |
|---|---|
| United States | 41.2% |
| Germany | 6.8% |
| Japan | 3.5% |
The United States toxicology drug screening market has experienced significant growth in recent years, driven by factors such as
The United States has the maximum drug abuse rates globally, resulting in a high demand for toxicology drug screening tests. This country has an increasing trend of embracing point-of-care toxicology drug screening tests. These tests are gaining popularity in emergency departments, rehabilitation centers, and workplaces. The reason behind their popularity lies in their ability to provide rapid results, convenience, and cost-effectiveness.
Workplace substance use is regulated by various federal requirements, including the Drug-Free Workplace Act of 1988, which specifically addresses this issue. These laws mandate certain employers to implement measures against drug use in the workplace, such as the development of a written policy.
Traditional drug screening methods are being replaced by advanced technologies such as liquid chromatography-mass spectrometry (LC-MS) and immunoassays. These methods offer higher accuracy and sensitivity, thereby boosting their adoption in the Germany toxicology drug screening market. Germany is facing a growing concern regarding substance abuse, including illegal drugs and prescription medications. This has further fueled the need for toxicology drug screening to identify and address drug-related issues.
In Germany, there is no clear or particular legislation governing drug tests. The basic principles and legislative regulations on the collecting and use of health-related data are applicable to drug testing during the pre-employment stage and at the workplace. According to the Federal Data Protection Act's section 4 subsection, the subject must be notified about the data that is going to be collected. The law's guidelines must be followed if the data must be maintained after collection.
There is a growing trend of workplace drug testing in Japan, driven by the need to maintain a safe and productive work environment. Many companies have started implementing drug testing programs to ensure the well-being of their employees and prevent substance abuse-related incidents.
Japan has a well-established healthcare system with significant healthcare expenditures. The government's focus on healthcare infrastructure development and increasing healthcare spending further supports the growth of the Japan toxicology drug screening market.
Japan has stringent regulations in place for drug testing and toxicology screening. The Ministry of Health, Labor, and Welfare (MHLW) regulates and oversees the approval process for diagnostic devices and ensures compliance with safety and quality standards. This regulatory environment creates opportunities for companies offering compliant toxicology screening solutions.
| Countries | Value CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 8.2% |
| China | 12.8% |
| India | 10.8% |
The United Kingdom has witnessed a growing emphasis on workplace drug testing due to the rising concerns regarding drug abuse in various industries. In this country, many firms have made screening a component of their drug and alcohol policies. In the past ten years, workplace drug testing has transformed from a controversial tactic viewed as an unfair ploy by employers to a legally justifiable option. Its prevalence has increased since 2014 and is now considered a standard practice in safety-critical industries. This trend is driving the United Kingdom toxicology drug screening market.
In the United Kingdom, drug testing is permitted. However, there are rules that companies must go with. Organizations conducting drug screening must adhere to guidelines and standards set by regulatory bodies such as the National Institute for Health and Care Excellence (NICE). This regulatory environment ensures the quality and reliability of drug screening services in the country.
The China toxicology drug screening market has been witnessing significant growth over the past few years. China's pharmaceutical industry has experienced substantial expansion, driven by increasing urbanization, a rising aging population, and improved healthcare infrastructure. With urbanization and social changes, drug abuse has become a significant concern in China. This has driven the demand for toxicology drug screening tests, both in workplace screening and rehabilitation centers.
China's rapid economic growth has resulted in higher healthcare spending. The government's initiatives to improve healthcare access and quality have led to increased investment in healthcare facilities and diagnostic technologies, including toxicology drug screening. The Drug Administration Law of the People's Republic of China became effective on December 1, 2019. The regulatory framework for toxicology drug screening in China is continually evolving, leading to market growth.
The increasing prevalence of drug abuse, stringent regulations for workplace drug testing, and the growing awareness about the adverse effects of substance abuse are driving the demand for toxicology drug screening. India's rapid economic growth and increasing disposable incomes are also fueling the demand for toxicology drug screening products and services.
India has seen a surge in substance abuse cases, including opioids, cannabis, and pharmaceutical drugs. This has created a pressing need for effective drug screening measures to identify and address drug abuse issues. The Indian government is actively working on strengthening drug abuse prevention measures. A pharmaceutical company needs the drug controller general's approval for a new prescription medicine to be sold in India.
| Segment | 2022 Value Share in Global Market |
|---|---|
| Acute Systemic Toxicity | 57.1% |
| Pharma and Biopharma Companies | 42.7% |
Acute systemic toxicity testing is a crucial component of drug development and safety assessment. It involves evaluating the adverse effects of a substance when administered systemically to determine its potential toxicity. Regulatory requirements play a crucial role. Regulatory bodies such as the Food and Drug Administration in the United States and the European Medicines Agency in Europe often demand acute systemic toxicity data as part of the preclinical safety assessment for drug approval. Meeting these requirements drives the demand for this testing segment.
Acute systemic toxicity testing provides valuable insights into the potentially harmful effects of a drug or chemical on various organs and systems in the body. This information is vital in identifying and assessing potential risks during drug development and screening processes. Moreover, acute systemic toxicity testing allows for early-stage screening and comparative analysis of different compounds or formulations. Resources and effort can be saved by identifying and eliminating toxic substances in the early stages.
Pharma and biopharma companies hold a dominant position in the toxicology drug screening market for several key reasons. Firstly, these companies heavily invest in research and development activities, relying on toxicology drug screening to evaluate the safety and efficacy of their drug candidates. This demand arises from the need to comply with stringent regulatory requirements and ensure their products meet safety standards. Pharma and biopharma companies conduct comprehensive toxicology screening to assess potential adverse effects and determine optimal dosage levels. Their adherence to regulatory compliance drives the demand for toxicology screening services.
The scale and resources of these companies contribute to their dominance. They possess the financial capacity to invest in advanced screening technologies and equipment, operate well-equipped laboratories, employ expert toxicologists, and access a wide range of biological samples for testing. Their large-scale operations allow them to conduct extensive toxicology studies, consolidating their position in the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
A wide array of toxicology drug screening market opportunities are opened up by the emerging start-ups in the toxicology drug screening market.
Examples:
Increasing innovation and efficiency in the pharmaceutical, chemical, and cosmetic sectors, while also contributing to the replacement, refinement, and reduction of animal testing.
Newormics' first product, a microfluidic-based technology, provides fast automated phenotyping of humanised C. elegans disease models and selects leads to address the unmet demand for HCS employing humanised animal models.
The toxicology drug screening market is consolidated and fairly competitive, with a few prominent competitors capturing major chunk of toxicology drug screening market share.
Some of the recent developments in the market are:
The market is slated to achieve US$ 70.80 billion by 2033.
The market is anticipated to expand at a CAGR of 10.5%.
North America holds monopoly in the market with a massive share of 43.1%.
The market is consolidated by surging drug abuse and strict government laws.
China exhibits a rampant growth of 12.8% CAGR.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033 5.3.1. Monitoring and logging 5.3.2. Security 5.3.3. Storage and continuous integration/continuous deployment 5.3.4. Management and orchestration 5.3.5. Networking and data management services 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033 6.3.1. Acute Systemic Toxicity 6.3.2. Dermal Toxicity 6.3.3. Carcinogenicity 6.3.4. Ocular Toxicity 6.3.5. Genotoxicity 6.3.6. Neurotoxicity 6.3.7. Organ-Specific Toxicity 6.4. Y-o-Y Growth Trend Analysis By Test Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Test Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology Type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Technology Type, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology Type, 2023 to 2033 7.3.1. High-Throughput Screening 7.3.2. Genomics 7.3.3. Transcriptomics 7.3.4. Toxicogenomics 7.3.5. Molecular Screening 7.4. Y-o-Y Growth Trend Analysis By Technology Type, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Technology Type, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By End Use, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use, 2023 to 2033 8.3.1. Hospitals and Trauma Centers 8.3.2. Forensic Laboratories 8.3.3. Diagnostic Laboratories 8.3.4. Rehabilitation Centers 8.3.5. Pharmaceutical & Biotechnology Companies 8.4. Y-o-Y Growth Trend Analysis By End Use, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By End Use, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. South Asia and Pacific 9.3.6. East Asia 9.3.7. Middle East and Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Product Type 10.2.3. By Test Type 10.2.4. By Technology Type 10.2.5. By End Use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product Type 10.3.3. By Test Type 10.3.4. By Technology Type 10.3.5. By End Use 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Product Type 11.2.3. By Test Type 11.2.4. By Technology Type 11.2.5. By End Use 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product Type 11.3.3. By Test Type 11.3.4. By Technology Type 11.3.5. By End Use 11.4. Key Takeaways 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. UK 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Western Europe 12.2.2. By Product Type 12.2.3. By Test Type 12.2.4. By Technology Type 12.2.5. By End Use 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product Type 12.3.3. By Test Type 12.3.4. By Technology Type 12.3.5. By End Use 12.4. Key Takeaways 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Poland 13.2.1.2. Russia 13.2.1.3. Czech Republic 13.2.1.4. Romania 13.2.1.5. Rest of Eastern Europe 13.2.2. By Product Type 13.2.3. By Test Type 13.2.4. By Technology Type 13.2.5. By End Use 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product Type 13.3.3. By Test Type 13.3.4. By Technology Type 13.3.5. By End Use 13.4. Key Takeaways 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Bangladesh 14.2.1.3. Australia 14.2.1.4. New Zealand 14.2.1.5. Rest of South Asia and Pacific 14.2.2. By Product Type 14.2.3. By Test Type 14.2.4. By Technology Type 14.2.5. By End Use 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product Type 14.3.3. By Test Type 14.3.4. By Technology Type 14.3.5. By End Use 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Product Type 15.2.3. By Test Type 15.2.4. By Technology Type 15.2.5. By End Use 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product Type 15.3.3. By Test Type 15.3.4. By Technology Type 15.3.5. By End Use 15.4. Key Takeaways 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Product Type 16.2.3. By Test Type 16.2.4. By Technology Type 16.2.5. By End Use 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Product Type 16.3.3. By Test Type 16.3.4. By Technology Type 16.3.5. By End Use 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Product Type 17.1.2.2. By Test Type 17.1.2.3. By Technology Type 17.1.2.4. By End Use 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Product Type 17.2.2.2. By Test Type 17.2.2.3. By Technology Type 17.2.2.4. By End Use 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Product Type 17.3.2.2. By Test Type 17.3.2.3. By Technology Type 17.3.2.4. By End Use 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Product Type 17.4.2.2. By Test Type 17.4.2.3. By Technology Type 17.4.2.4. By End Use 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Product Type 17.5.2.2. By Test Type 17.5.2.3. By Technology Type 17.5.2.4. By End Use 17.6. UK 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Product Type 17.6.2.2. By Test Type 17.6.2.3. By Technology Type 17.6.2.4. By End Use 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Product Type 17.7.2.2. By Test Type 17.7.2.3. By Technology Type 17.7.2.4. By End Use 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Product Type 17.8.2.2. By Test Type 17.8.2.3. By Technology Type 17.8.2.4. By End Use 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Product Type 17.9.2.2. By Test Type 17.9.2.3. By Technology Type 17.9.2.4. By End Use 17.10. Poland 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Product Type 17.10.2.2. By Test Type 17.10.2.3. By Technology Type 17.10.2.4. By End Use 17.11. Russia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Product Type 17.11.2.2. By Test Type 17.11.2.3. By Technology Type 17.11.2.4. By End Use 17.12. Czech Republic 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Product Type 17.12.2.2. By Test Type 17.12.2.3. By Technology Type 17.12.2.4. By End Use 17.13. Romania 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Product Type 17.13.2.2. By Test Type 17.13.2.3. By Technology Type 17.13.2.4. By End Use 17.14. India 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Product Type 17.14.2.2. By Test Type 17.14.2.3. By Technology Type 17.14.2.4. By End Use 17.15. Bangladesh 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Product Type 17.15.2.2. By Test Type 17.15.2.3. By Technology Type 17.15.2.4. By End Use 17.16. Australia 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Product Type 17.16.2.2. By Test Type 17.16.2.3. By Technology Type 17.16.2.4. By End Use 17.17. New Zealand 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Product Type 17.17.2.2. By Test Type 17.17.2.3. By Technology Type 17.17.2.4. By End Use 17.18. China 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Product Type 17.18.2.2. By Test Type 17.18.2.3. By Technology Type 17.18.2.4. By End Use 17.19. Japan 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Product Type 17.19.2.2. By Test Type 17.19.2.3. By Technology Type 17.19.2.4. By End Use 17.20. South Korea 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Product Type 17.20.2.2. By Test Type 17.20.2.3. By Technology Type 17.20.2.4. By End Use 17.21. GCC Countries 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Product Type 17.21.2.2. By Test Type 17.21.2.3. By Technology Type 17.21.2.4. By End Use 17.22. South Africa 17.22.1. Pricing Analysis 17.22.2. Market Share Analysis, 2022 17.22.2.1. By Product Type 17.22.2.2. By Test Type 17.22.2.3. By Technology Type 17.22.2.4. By End Use 17.23. Israel 17.23.1. Pricing Analysis 17.23.2. Market Share Analysis, 2022 17.23.2.1. By Product Type 17.23.2.2. By Test Type 17.23.2.3. By Technology Type 17.23.2.4. By End Use 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Product Type 18.3.3. By Test Type 18.3.4. By Technology Type 18.3.5. By End Use 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Agilent Technologies, Inc. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Covance, Inc. 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Bio-Rad Laboratories, Inc. 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. General Electric Company 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. BioReliance, Inc. 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Thermo Fisher Scientific, Inc. 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Eurofins Scientific SE 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. GE Healthcare 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Quest Diagnostics 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Alere, Inc. 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.11. Enzo Life Sciences, Inc. 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Toxicology Drug Screening Market
